Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists for cancer treatment
Summary
USPTO granted Patent US12590096B2 to BeOne Medicines GmbH for an imidazo[2,1-f][1,2,4]triazin-4-amine derivative as a TLR8 agonist for treating cancers. The patent contains 18 claims and was filed on July 31, 2020 (Application No. 17632027). The compound is classified under 12 CPC codes spanning antineoplastic, antiviral, and anti-inflammatory applications.
What changed
USPTO granted Patent US12590096B2 to BeOne Medicines GmbH covering imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR8 agonists for cancer treatment. The patent includes 18 claims and was granted on March 31, 2026, with a filing date of July 31, 2020. CPC classifications span oncology (A61P 35/00), antivirals (A61P 31/12, 31/14, 31/16), anti-inflammatory (A61P 37/08), and other therapeutic indications.
Pharmaceutical companies developing TLR8-targeted cancer immunotherapies should conduct freedom-to-operate analyses to assess potential patent infringement risks. IP departments should review this grant for competitive landscape implications and update portfolio monitoring systems accordingly. No immediate compliance deadlines or penalties are associated with this patent grant.
What to do next
- Conduct freedom-to-operate analysis for any TLR8 agonist development programs
- Review competitive patent landscape for TLR8-targeted oncology compounds
- Update IP portfolio tracking systems with grant date and term calculations
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists
Grant US12590096B2 Kind: B2 Mar 31, 2026
Assignee
BeOne Medicines | GmbH
Inventors
Guoliang Zhang, Jianzhuang Miao, Ce Wang
Abstract
Disclosed are an imidazo[2,1-f][1,2,4]triazin-4-amine derivative used as a TLR8 agonist or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same. Further disclosed is a method for treating cancers using the imidazo[2,1-f][1,2,4]triazin-4-amine derivative or the stereoisomer thereof or the pharmaceutically acceptable salt thereof as a TLR8 agonist.
CPC Classifications
C07D 487/04 C07D 519/00 A61P 1/16 A61P 11/02 A61P 11/06 A61P 31/12 A61P 31/14 A61P 31/16 A61P 35/00 A61P 37/08 A61P 1/04 A61K 31/53
Filing Date
2020-07-31
Application No.
17632027
Claims
18
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.